The US Patent and Trademark Office (USPTO) has granted Implanet two new patents for the Jazz platform.
These patents bring the company’s total number of patents to 24 for the Jazz platform.
The platform includes the Jazz Lock, the Jazz Claw, the Jazz Frame and the Jazz Band. It is intended to treat all degenerative, scoliosis-deformity and trauma-tumour pathologies in adolescents and adults.
Régis Le Couedic, Implanet’s Product Development & Manufacturing director, says, “These two new US patents expand our protection on this highly competitive market… We will continue to expand the scope of protection covering our Jazz platform and future innovations.”
Independent radiological results for the Jazz Band were presented at the Scoliosis Research Society’s Annual Meeting in Philadelphia, USA (SRS; 6–9 September). A white paper concerned with adolescent idiopathic scoliosis discussed analyses of 3D radiological reconstructions with EOS 3D Service (EOS Imaging).
The US Food and Drug Administration approved the latest addition to the platform—the Jazz Passer—earlier this month. The Passer is a variation on the Jazz Braid, which itself was launched in the USA and Europe earlier this year.
Last year, Implanet announced the initiation of a prospective, multicentre clinical study of the Jazz Band. The study is designed to document the outcomes of the Jazz Band in adult degenerative and adult deformity indications. Implanet partnered with TFS International, a professional contract research organisation, to help promote a scientifically robust study design and execution.
This adds to an earlier prospective, multicentre Jazz Band study which enrolled its first patient in 2015. The patient was enrolled at Ohio State University in Columbus, USA. At the time, principal investigator H Francis Farhadi expressed excitement at the prospect of analysing the potential clinical and economic benefits of sublaminar band technology in complex spinal fusions.”